Stock Research: Sanofi India

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Sanofi India

NSI:SANOFI INE058A01010
56
  • Value
    48
  • Growth
    12
  • Safety
    Safety
    77
  • Combined
    42
  • Sentiment
    80
  • 360° View
    360° View
    56
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Sanofi India Limited manufactures and trades drugs and pharmaceuticals. The company focuses on therapeutic areas including diabetes (Lantus, Toustar), epilepsy (Frisium), cardiology (Cardace), allergy (Allegra, Avil), and pain care (Combiflam). It operates mainly in India, with a manufacturing facility in Goa and around 12 contract manufacturing organizations. In the last fiscal year, the company had a market cap of $1577 million, profits of $119 million, revenue of $235 million, and 991 employees.

more
Index
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 19-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
48 35 43 55
Growth
12 11 31 7
Safety
Safety
77 83 75 97
Sentiment
80 83 45 94
360° View
360° View
56 59 43 79
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
63 97 87 97
Opinions Change
50 50 50 50
Pro Holdings
n/a 50 25 92
Market Pulse
83 84 29 27
Sentiment
80 83 45 94
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
48 35 43 55
Growth
12 11 31 7
Safety Safety
77 83 75 97
Combined
42 23 47 59
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
52 36 29 39
Price vs. Earnings (P/E)
35 42 50 50
Price vs. Book (P/B)
12 10 14 43
Dividend Yield
74 67 76 82
Value
48 35 43 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
50 23 32 8
Profit Growth
18 12 59 32
Capital Growth
28 19 17 9
Stock Returns
18 47 83 25
Growth
12 11 31 7
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
79 84 82 92
Refinancing
39 32 32 48
Liquidity
88 90 88 92
Safety Safety
77 83 75 97

Similar Stocks

Discover high‑ranked alternatives to Sanofi India and broaden your portfolio horizons.

Grifols

MCE:GRF
Country: Spain
Industry: Biotechnology
Size: X-Large
Full Stock Analysis

L.D.C.

PAR:LOUP
Country: France
Industry: Packaged Foods & Meats
Size: Large
Full Stock Analysis

Rubis

PAR:RUI
Country: France
Industry: Gas Utilities
Size: Large
Full Stock Analysis

Krka

LJU:KRKG
Country: Slovenia
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Frequently Asked
Questions

The stock offers good value, safe financing, and positive sentiment. However, it has below-average growth expectations. It is well-suited for conservative buy-and-hold investors who prioritize stability and low valuation over growth.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: